60.93
-0.4(-0.65%)
Currency In USD
| Previous Close | 61.33 |
| Open | 62 |
| Day High | 62.55 |
| Day Low | 59.04 |
| 52-Week High | 86.53 |
| 52-Week Low | 40 |
| Volume | 25,246 |
| Average Volume | 40,255 |
| Market Cap | 1.94B |
| PE | -51.64 |
| EPS | -1.18 |
| Moving Average 50 Days | 61.91 |
| Moving Average 200 Days | 59.04 |
| Change | -0.4 |
If you invested $1000 in Belite Bio, Inc (BLTE) since IPO date, it would be worth $5,753.54 as of May 09, 2025 at a share price of $60.93. Whereas If you bought $1000 worth of Belite Bio, Inc (BLTE) shares 2 years ago, it would be worth $2,417.86 as of May 09, 2025 at a share price of $60.93.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results
GlobeNewswire Inc.
May 07, 2025 12:00 PM GMT
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medi
Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting
GlobeNewswire Inc.
Apr 29, 2025 12:00 PM GMT
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet m
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
GlobeNewswire Inc.
Mar 17, 2025 10:00 AM GMT
SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company, today announced that its annual report on Form 20-F, containing audited consolidated financia